Cellebrite DI (NASDAQ:CLBT) Stock Rating Lowered by Wall Street Zen

Cellebrite DI (NASDAQ:CLBT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research firms have also recently commented on CLBT. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Bank of America upped their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Finally, Lake Street Capital raised their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Stock Performance

Shares of CLBT opened at $15.30 on Friday. Cellebrite DI has a 52-week low of $11.76 and a 52-week high of $20.86. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 49.35, a PEG ratio of 2.33 and a beta of 1.30. The business’s fifty day moving average is $15.61 and its 200-day moving average is $16.94.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.Cellebrite DI’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 EPS. As a group, research analysts forecast that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI in the third quarter valued at approximately $55,999,000. Granahan Investment Management LLC lifted its position in shares of Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after acquiring an additional 2,411,726 shares during the period. Capital International Investors acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $41,073,000. Invesco Ltd. boosted its stake in Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after acquiring an additional 2,054,644 shares in the last quarter. Finally, Pertento Partners LLP boosted its stake in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after acquiring an additional 1,702,574 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.